文献速递银屑病与炎症性皮肤病皮肤感染

IL-17与IL-23抑制剂治疗银屑病中结核再激活风险:范式转变的时机

Risk of tuberculosis reactivation with interleukin (IL)-17 and IL-23 inhibitors in psoriasis - time for a paradigm change.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2020-09-01

本文综述IL-17和IL-23抑制剂治疗银屑病时结核再激活的现有数据。鉴于TNF-α抑制剂已知增加潜伏结核再激活风险,而IL-17/23抑制剂临床与上市后监测数据提示其可能不携带同等风险,文章探讨了对潜伏结核感染管理策略的可能影响。

要点

  • IL-17与IL-23抑制剂治疗银屑病的结核再激活风险可能低于TNF-α抑制剂。
  • 临床数据提示IL-17/23并非抗结核免疫的关键因子,但需更多证据。
  • 现行所有生物制剂前结核筛查与潜伏结核预防性治疗策略或需重新评估。

核心结论

  • IL-17和IL-23抑制剂治疗银屑病可能不携带与TNF-α抑制剂相同的结核再激活风险,或需重新审视现行潜伏结核管理策略。

研究设计与样本

  • 本文为综述,汇总IL-17和IL-23抑制剂治疗银屑病后结核再激活的现有数据,包括临床研究及上市后监测。

主要发现

  • 临床研究与上市后监测数据提示IL-17和IL-23抑制剂可能不关键影响抗结核免疫反应。
  • 临床前研究显示IL-17和IL-23细胞因子对结核分枝杆菌感染可能具有防御作用。

关键数值与推荐

  • 国际指南建议所有生物制剂开始治疗前筛查结核,潜伏结核者行化学预防并每年筛查。
  • 抗结核治疗可产生显著副作用且存在禁忌症,需仔细权衡风险获益。

临床怎么用

  • 对使用IL-17或IL-23抑制剂的银屑病患者,可基于最新证据重新评估潜伏结核筛查与预防性治疗的必需性。

局限性

  • 本文为综述,结论基于现有临床研究与上市后监测数据,尚需更多前瞻性研究确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Tuberculosis is an infectious disease with a major global impact, ranked in the top 10 mortality causes worldwide. In an immunocompetent individual, the host defence mechanisms control Mycobacterium tuberculosis infection and induce the latent form of the disease. However, in the presence of diseases or therapies, which exert an immunosuppressive effect, latent tuberculosis can be re-activated. Psoriasis is an immune-mediated, inflammatory disease, and its treatment has rapidly evolved over the last few years. It has long been recognized that the tumour necrosis factor (TNF)-α inhibitors are associated with increased risk of reactivation of latent tuberculosis infection. Thus, international guidelines have been suggesting tuberculosis screening before starting the treatment with all biological agents since then. In addition, the institution of chemoprophylaxis in the presence of latent tuberculosis and the annual screening for tuberculosis thereafter have also been indicated. However, anti-tuberculosis treatments can have significant side-effects and there are currently several contraindications to their use. The risk benefit of starting anti-tuberculous treatment should be carefully weighed up. The emergence of new biological drugs for the treatment of psoriasis, such as interleukin (IL)-17 and IL-23 inhibitors, has reignited the subject of tuberculosis reactivation as it is possible that IL-17 and 23 blockade do not carry the same risk of TB reactivation as TNF-α inhibitors. Although preclinical studies have shown that cytokines IL-17 and IL-23 have a possible role against infection with M. tuberculosis, data from clinical trials and post-marketing surveillance with drugs that inhibit these cytokines appear to suggest that they are not crucial to this response. In this article, we review the available data on tuberculosis reactivation after the treatment of psoriasis with IL-17 and IL-23 inhibitors, and its possible impact on the way we currently manage latent tuberculosis infection before or after starting treatment with these new drugs.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Nogueira M, Warren RB, Torres T, et al. Risk of tuberculosis reactivation with interleukin (IL)-17 and IL-23 inhibitors in psoriasis - time for a paradigm change. J Eur Acad Dermatol Venereol. 2020. PMID: 32790003. doi:10.1111/jdv.16866

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。